Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
sezary syndrome
MeSH D012751 - sezary syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008232:
Lymphoproliferative disorders
2 Companies
2 Drugs
$
Success rate
D016410:
T-cell lymphoma cutaneous
13 Companies
3 Drugs
$
Success rate
D012751:
Sezary syndrome
5 Companies
7 Drugs
$
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
56
%
18/32
Phase 2
0
%
0/25
Phase 3
80
%
8/10
Approved:
8
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Kyowa Kirin
Mogamulizumab
Merck & Co
Ribavirin
,
Interferon alfa-2b
,
Peginterferon alfa-2b
Roche
Ribavirin
,
Peginterferon alfa-2a
,
Interferon alfa-2a
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use